I reckon next news will be official ethics approval hopefully accompanied with a timeline for clinical trials. We may even see third party developments with regards to trial partners & grants. Obviously this is a long term play.
It it seems they are pretty well funded for the medium term and access to further non-dilutionary grants is always possible considering the impact/cost of both stroke and NAFLD on society.
Ann: Investor Presentation, page-28
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.98 |
Change
0.020(1.02%) |
Mkt cap ! $174.4M | |||
| Open | High | Low | Value | Volume |
| $1.96 | $1.98 | $1.94 | $169.4K | 86.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 282 | $1.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.98 | 22897 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| EMV (ASX) Chart |
